Livforsakringsbolaget Skandia Omsesidigt Has $8.13 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Livforsakringsbolaget Skandia Omsesidigt raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 100,372 shares of the biopharmaceutical company’s stock after buying an additional 1,235 shares during the period. Gilead Sciences accounts for about 0.8% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio, making the stock its 28th largest holding. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Gilead Sciences were worth $8,131,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Altshuler Shaham Ltd grew its holdings in Gilead Sciences by 7.0% in the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 121 shares during the period. Nilsine Partners LLC grew its holdings in Gilead Sciences by 1.1% in the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 127 shares during the period. Etesian Wealth Advisors Inc. grew its holdings in Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 128 shares during the period. Financial Counselors Inc. grew its holdings in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares during the period. Finally, Revolve Wealth Partners LLC grew its holdings in Gilead Sciences by 3.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GILD. Mizuho reduced their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Oppenheimer reduced their price objective on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, February 12th. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Royal Bank of Canada reduced their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a report on Wednesday, February 14th. Finally, Wells Fargo & Company reduced their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $85.36.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now owns 100,936 shares in the company, valued at $7,386,496.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock traded down $0.38 during mid-day trading on Wednesday, hitting $66.93. The company had a trading volume of 5,283,342 shares, compared to its average volume of 7,319,696. The firm has a market cap of $83.33 billion, a PE ratio of 14.96, a price-to-earnings-growth ratio of 0.86 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences, Inc. has a 12 month low of $66.89 and a 12 month high of $87.86. The stock’s fifty day moving average price is $72.40 and its two-hundred day moving average price is $76.73.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business’s revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.67 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.06 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a $0.77 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.60%. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.